Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

• Publication date: September 2011

Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Summary GlobalData, the industry analysis specialist, has released its new report, “Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global acute ischemic stroke therapeutics market. The report identifies the key trends...

Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Acute Ischemic Stroke (AIS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global acute ischemic stroke therapeutics market. The report identifies the key trends shaping and driving the global acute ischemic stroke therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global acute ischemic stroke therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the acute ischemic stroke market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) acute ischemic stroke therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as immunomodulators, NMDA receptor antagonists, platelet inhibitor, polyketide antibiotics, and recombinant proteins amongst others.
- Analysis of the current and future competition in the seven key countries acute ischemic stroke therapeutics market. Key market players covered are Celgene Corporation, Cidat C.V. Corrimum Gmbh, D-Pharm Ltd., H Lundbeck A/S, Mitsubhishi Tanabe Pharma, Panacea Pharmaceuticals, Pfizer, Inc., Sanofi, Stemedica Cell Technologies, Vernalis PLC.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the acute ischemic stroke market.
- Analysis of key recent licensing and partnership agreements in acute ischemic stroke therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global acute ischemic stroke market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global acute ischemic stroke market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global acute ischemic stroke market landscape? – Identify, understand and capitalize.

Therapy Industry in the United Kingdom

1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Acute Ischemic Stroke Therapeutics - Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 9
2.3.1 Pathophysiology 10
2.4 Signs and Symptoms 11
2.5 Diagnosis 12
2.6 Treatment and Management Options 13
2.6.1 Referral Pathway 22
2.7 GlobalData Pipeline Report Guidance 23
3 Acute Ischemic Stroke Therapeutics - Market Characterization 24
3.1 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - Global 24
3.2 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - Global 25
3.3 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - The US 26
3.4 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - The US 27
3.5 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - France 28
3.6 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - France 29
3.7 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - Germany 30
3.8 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - Germany 31
3.9 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - Italy 32
3.10 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - Italy 33
3.11 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - Spain 34
3.12 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - Spain 35
3.13 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - The UK 36
3.14 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - The UK 37
3.15 Acute Ischemic Stroke Therapeutics Market Size (2005-2010) - Japan 38
3.16 Acute Ischemic Stroke Therapeutics Market Forecast (2010-2018) - Japan 39
3.17 Drivers and Barriers for the Acute Ischemic Stroke Therapeutics Market 40
3.17.1 Drivers for the Acute Ischemic Stroke Therapeutics Market 40
3.17.2 Barriers for the Acute Ischemic Stroke Therapeutics Market 40
3.18 Opportunity and Unmet Need Analysis 41
3.19 Key Takeaway 42
4 Acute Ischemic Stroke Therapeutics - Competitive Assessment 43
4.1 Overview 43
4.1.1 Strategic Competitor Assessment 43
4.2 Product Profiles for the Major Marketed Products in the Acute Ischemic Stroke Therapeutics Market 44
4.2.1 Activase (alteplase) 44
4.2.2 Plavix (clopidogrel) 45
4.2.3 Radicut (edaravone) 46
4.3 Key Takeaway 47
5 Acute Ischemic Stroke Therapeutics - Pipeline Assessment 48
5.1 Overview 48
5.2 Strategic Pipeline Assessment 48
5.3 Acute Ischemic Stroke Therapeutics Pipeline - Pipeline by Phases of Development 48
5.3.1 Acute Ischemic Stroke Therapeutics - Filed Pipeline 49
5.3.2 Acute Ischemic Stroke Therapeutics - Phase III Pipeline 49
5.3.3 Acute Ischemic Stroke Therapeutics - Phase II Pipeline 50
5.3.4 Acute Ischemic Stroke Therapeutics - Phase I Pipeline 51
5.3.5 Acute Ischemic Stroke Therapeutics - Pre-Clinical Pipeline 51
5.3.6 Acute Ischemic Stroke Therapeutics - Discovery Pipeline 51
5.3.7 Technology Trends Analytical Framework 52
5.4 Acute Ischemic Stroke Therapeutics Market - Pipeline by Mechanism of Action 54
5.5 Phase III Drugs Under Development 55
5.5.1 Desmoteplase 55
5.5.2 DP-b99 55
5.5.3 Dapsone 56
5.6 Key Takeaway 57
6 Acute Ischemic Stroke Therapeutics - Clinical Trials Mapping 58
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 58
6.2 Clinical Trials by Phase 59
6.3 Clinical Trials by Trial Status 60
6.4 Prominent Sponsors 61
6.5 Top Companies Participating in Acute Ischemic Stroke Therapeutics Clinical Trials 63
7 Strategic Assessment 64
7.1 Key Events Impacting the Future Market 64
7.2 Acute Ischemic Stroke Therapeutics - Implications for Future Market Competition 65
8 Acute Ischemic Stroke Therapeutics - Future Players 66
8.1 Introduction 66
8.2 Company Profiles 67
8.2.1 H Lundbeck A/S 67
8.2.2 D-Pharm, Ltd. 69
8.2.3 Aldagen, Inc. 70
8.2.4 Celgene Corparation 71
8.2.5 M’s Science Corporation 73
8.2.6 Mitsubishi Tanabe Pharma Corporation 74
8.2.7 SYGNIS Pharma AG 76
8.2.8 Stemedica Cell Technologies, Inc. 77
8.2.9 Thrombotech Technologies Ltd. 77
8.2.10 Vernalis PLC 78
8.3 Other Companies in the Pipeline 80
9 Acute Ischemic Stroke Therapeutics - Licensing and Partnership Deals 82
10 Acute Ischemic Stroke Therapeutics - Appendix 84
10.1 Market Definitions 84
10.2 Abbreviations 84
10.3 Methodology 85
10.3.1 Coverage 85
10.3.2 Secondary Research 86
10.3.3 Forecasting 86
10.3.4 Primary Research 87
10.3.5 Expert Panel Validation 88
10.4 Contact Us 88
10.5 Disclaimer 88
10.6 Bibliography 88

List of Tables

Table 1: Vascular Supply to the Brain 7
Table 2: Stroke Statistics (2003-2007), The US 9
Table 3: Initial Management of Ischemic Stroke 13
Table 4: The National Institutes of Health Stroke Scale 14
Table 5: Criteria for Thrombolysis of Patients with Acute Ischemic Stroke using rtPA 16
Table 6: Recommendations for the Use of Anti-Coagulant and Anti-Platelet Agents in Patients with Acute Ischemic Stroke 18
Table 7: Acute Ischemic Stroke Therapeutics Market, Global, Revenue ($m), 2005 - 2010 24
Table 8: Acute Ischemic Stroke Therapeutics Market, Global, Forecast ($m), 2010 - 2018 25
Table 9: Acute Ischemic Stroke Therapeutics Market, The US, Revenue ($m), 2005 - 2010 26
Table 10: Acute Ischemic Stroke Therapeutics Market, The US, Forecasts ($m), 2010 - 2018 27
Table 11: Acute Ischemic Stroke Therapeutics Market, France, Revenue ($m), 2005 - 2010 28
Table 12: Acute Ischemic Stroke Therapeutics Market, France, Forecasts ($m), 2010 - 2018 29
Table 13: Acute Ischemic Stroke Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 30
Table 14: Acute Ischemic Stroke Therapeutics Market, Germany, Forecasts ($m), 2010 - 2018 31
Table 15: Acute Ischemic Stroke Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 32
Table 16: Acute Ischemic Stroke Therapeutics Market, Italy, Forecasts ($m), 2010 - 2018 33
Table 17: Acute Ischemic Stroke Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 34
Table 18: Acute Ischemic Stroke Therapeutics Market, Spain, Forecasts ($m), 2010 - 2018 35
Table 19: Acute Ischemic Stroke Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 36
Table 20: Acute Ischemic Stroke Therapeutics Market, The UK, Forecasts ($m), 2010 - 2018 37
Table 21: Acute Ischemic Stroke Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 38
Table 22: Acute Ischemic Stroke Therapeutics Market, Japan, Forecasts ($m), 2010 - 2018 39
Table 23: Outcome Events in CAPRIE Primary Analysis 45
Table 24: Edaravone - Efficacy in Acute Ischemic Stroke Patients - Randomized, Placebo-Controlled Study 46
Table 25: Acute Ischemic Stroke Therapeutics, Filed Pipeline, 2011 49
Table 26: Acute Ischemic Stroke Therapeutics, Phase III Pipeline, 2011 49
Table 27: Acute Ischemic Stroke Therapeutics, Phase II Pipeline, 2011 50
Table 28: Acute Ischemic Stroke Therapeutics, Phase I Pipeline, 2011 51
Table 29: Acute Ischemic Stroke Therapeutics, Pre-Clinical Pipeline, 2011 51
Table 30: Acute Ischemic Stroke Therapeutics, Discovery Pipeline, 2011 51
Table 31: Mechanisms of Action that Constitute the “Others” in the Pipeline 54
Table 32: Acute Ischemic Stroke Therapeutics, Clinical Trials by Country, 2011 58
Table 33: Acute Ischemic Stroke Therapeutics, Clinical Trials by Phase, 2011 59
Table 34: Acute Ischemic Stroke Therapeutics, Overall Sponsors, 2011 61
Table 35: Acute Ischemic Stroke Therapeutics, Prominent Sponsors, 2011 62
Table 36: Acute Ischemic Stroke Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 63
Table 37: H. Lundbeck A/S, Inflammatory and Infectious Diseases, Pipeline, 2011 68
Table 38: H. Lundbeck A/S, Acute Ischemic Stroke, Pipeline, 2011 68
Table 39: D-Pharm Ltd., CNS Pipeline, 2011 69
Table 40: D-Pharm Ltd., Acute Ischemic Stroke Pipeline, 2011 69
Table 41: Aldagen, Inc., CNS Pipeline, 2011 70
Table 42: Aldagen, Inc., Acute Ischemic Stroke Pipeline, 2011 70
Table 43: Celgene Corporation, CNS Pipeline, 2011 73
Table 44: Celgene Corporation, Acute Ischemic Stroke Pipeline, 2011 73
Table 45: M’s Science Corporation, CNS Pipeline, 2011 73
Table 46: M’s Science Corporation, Acute Ischemic Stroke Pipeline, 2011 73
Table 47: Mitsubishi Tanabe Pharma Corporation, CNS Pipeline, 2011 75
Table 48: Mitsubishi Tanabe Pharma Corporation, CNS Pipeline, 2011 75
Table 49: SYGNIS Pharma AG, Acute Ischemic Stroke Pipeline, 2011 76
Table 50: SYGNIS Pharma AG, Acute Ischemic Stroke Pipeline, 2011 76
Table 51: SYGNIS Pharma AG, Acute Ischemic Stroke Pipeline, 2011 77
Table 52: Thrombotech Technologies, Acute Ischemic Stroke Pipeline, 2011 77
Table 53: Vernalis PLC, CNS Pipeline, 2011 79
Table 54: Vernalis PLC, Acute Ischemic Stroke Pipeline, 2011 79
Table 55: Acute Ischemic Stroke Therapeutics, Other Companies in the Pipeline 80
Table 56: Acute Ischemic Stroke Therapeutics, Deals, 2008-2011 82

List of Figures

Figure 1: Causes of Ischemic Stroke 10
Figure 2: Axial Non-contrast Computed Tomography (NCCT) Showing Diffuse Hypodensity in the Brain 11
Figure 3: Acute Ischemic Stroke Therapeutics, Algorithm for the Management of Patients with Acute Ischemic Stroke 17
Figure 4: Acute Ischemic Stroke Therapeutics, Treatment Protocol 19
Figure 5: Acute Ischemic Stroke Therapeutics, Treatment Algorithm 19
Figure 6: Acute Ischemic Stroke Therapeutics, Stroke Code for the Treatment of Acute Ischemic Stroke 20
Figure 7: Acute Ischemic Stroke, Referral Pathway 22
Figure 8: Acute Ischemic Stroke Therapeutics Market, Global, Revenue ($m), 2005 - 2010 24
Figure 9: Acute Ischemic Stroke Therapeutics Market, Global, Forecast ($m), 2010 - 2018 25
Figure 10: Acute Ischemic Stroke Therapeutics Market, The US, Revenue ($m), 2005 - 2010 26
Figure 11: Acute Ischemic Stroke Therapeutics Market, The US, Forecast ($m), 2010 - 2018 27
Figure 12: Acute Ischemic Stroke Therapeutics Market, France, Revenue ($m), 2005 - 2010 28
Figure 13: Acute Ischemic Stroke Therapeutics Market, France, Forecast ($m), 2010 - 2018 29
Figure 14: Acute Ischemic Stroke Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 30
Figure 15: Acute Ischemic Stroke Therapeutics Market, Germany, Forecast ($m), 2010 - 2018 31
Figure 16: Acute Ischemic Stroke Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 32
Figure 17: Acute Ischemic Stroke Therapeutics Market, Italy, Forecast ($m), 2010 - 2018 33
Figure 18: Acute Ischemic Stroke Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 34
Figure 19: Acute Ischemic Stroke Therapeutics Market, Spain, Forecast ($m), 2010 - 2018 35
Figure 20: Acute Ischemic Stroke Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 36
Figure 21: Acute Ischemic Stroke Therapeutics Market, The UK, Forecast ($m), 2010 - 2018 37
Figure 22: Acute Ischemic Stroke Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 38
Figure 23: Acute Ischemic Stroke Therapeutics Market, Japan, Forecast ($m), 2010 - 2018 39
Figure 24: Opportunity and Unmet Need in the Acute Ischemic Stroke Therapeutics Market, Primary Treatment, 2010 41
Figure 25: Opportunity and Unmet Need in the Acute Ischemic Stroke Therapeutics Market, Maintenance Therapy, 2010 42
Figure 26: Acute Ischemic Stroke Therapeutics, Strategic Competitor Assessment, 2010 43
Figure 27: Acute Ischemic Stroke Therapeutics, Pipeline by Phase of Development, 2011 48
Figure 28: Acute Ischemic Stroke Therapeutics, Technology Trends Analytics Framework, 2011 52
Figure 29: Acute Ischemic Stroke Therapeutics, Technology Trends Analytics Framework, Description, 2011 53
Figure 30: Acute Ischemic Stroke Therapeutics, Pipeline by Mechanism of Action (%), 2011 54
Figure 31: Acute Ischemic Stroke Therapeutics, Clinical Trials by Country, 2011 58
Figure 32: Acute Ischemic Stroke Therapeutics, Clinical Trials by Phase (%), 2011 59
Figure 33: Acute Ischemic Stroke Therapeutics, Clinical Trials by Status (%), 2011 60
Figure 34: Acute Ischemic Stroke Therapeutics, Overall Sponsors (%), 2011 61
Figure 35: Acute Ischemic Stroke Therapeutics, Prominent Sponsors (%), 2011 62
Figure 36: Acute Ischemic Stroke Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 63
Figure 37: Acute Ischemic Stroke Therapeutics Market, Drivers and Barriers, 2011 64
Figure 38: Implications for Future Market Competition in the Acute Ischemic Stroke Market, 2011 65
Figure 39: Acute Ischemic Stroke Therapeutics Market - Pipeline by Company, 2010 66

Companies Mentioned

H Lundbeck A/S
D-Pharm, Ltd.
Aldagen, Inc.
Celgene Corparation
M’s Science Corporation
Mitsubishi Tanabe Pharma Corporation
SYGNIS Pharma AG
Stemedica Cell Technologies, Inc.
Thrombotech Technologies Ltd.
Vernalis PLC